MaxCyte (MXCT) Set to Post Earnings on Tuesday

MaxCyte (NASDAQ:MXCT) is expected to post its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect MaxCyte to post earnings of ($0.08) per share and revenue of $7.39 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. The company had revenue of $6.50 million during the quarter, compared to analysts’ expectations of $6.51 million. MaxCyte had a negative net margin of 114.77% and a negative return on equity of 18.92%. On average, analysts expect MaxCyte to post ($0.25) EPS for the current fiscal year and ($0.19) EPS for the next fiscal year.

MaxCyte Trading Down 3.1%

MXCT stock traded down $0.04 during mid-day trading on Tuesday, reaching $1.41. The company’s stock had a trading volume of 296,638 shares, compared to its average volume of 1,051,224. The company’s 50 day moving average is $1.26 and its two-hundred day moving average is $1.07. MaxCyte has a fifty-two week low of $0.64 and a fifty-two week high of $1.80. The stock has a market cap of $145.00 million, a PE ratio of -4.26 and a beta of 1.49.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. BTIG Research restated a “neutral” rating on shares of MaxCyte in a research report on Monday, August 24th. Weiss Ratings raised MaxCyte from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 22nd. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.00.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a life sciences company that develops technologies for engineering cells used in biopharmaceutical research and the development of cell-based therapies. Its platform is designed to help researchers modify cells efficiently for applications including cell therapy, gene editing, immuno-oncology and other advanced biological treatments.

The company’s primary offering is the ExPERT platform, which combines Flow Electroporation technology with specialized instruments, single-use processing assemblies, software and related support services.